secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088072
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports non-clinical proof-of-concept data for MT-401 OTS, expects first patient treatment H1 2024
--------------------------------------------------------------------------------

- Non-clinical data: MT-401 OTS killed AML cells in vitro with 2/8 HLA match, significantly reducing THP-1 cell growth.
- FDA cleared clinical protocol for MT-401 OTS in relapsed/refractory AML; inventory of 8 donor lines established.
- Single donor could treat ~40 patients; product stable >1 year; first patient treatment expected H1 2024.
- OTS strategy aims to reduce manufacturing cost and turnaround time to as little as 72 hours.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923088072/0001104659-23-088072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923088072/tm2320895d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer